• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·UK·Healthcare·EAH.L
Share

ECO Animal Health Group plc Stocks

£ 88.6Last Updated 09.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

£ 85.46M

£ 88.6
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

ECO Animal Health Group plc, established in 1972 and based in New Malden, United Kingdom, focuses on the worldwide research, regulatory approval, and distribution of veterinary pharmaceutical solutions. The company's offerings include Aivlosin, a macrolide antibiotic specifically formulated to address digestive and respiratory illnesses in pigs and poultry. Additionally, its product range encompasses various generic drugs like Ecomectin, Ecoheart, Ecotraz, and Ecomintic. These endectocides and other antiparasitics are designed to manage and prevent parasitic infestations such as worms, ticks, and lice across a diverse array of animals, including cattle, sheep, pigs, horses, and dogs. ECO Animal Health Group also provides Chlortetracycline and Oxytetracycline for treating bacterial infections in swine, fowl, and bovine animals.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, undervalu

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of EAH.L is 185 and suggests 106% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.07.2026 01:21

SK Hynix's First Day of Trading in the U.S. and Meta's Surge: The Market Bet on AI on Friday

11.07.2026 00:31

Meta Shares Are on Track for Their Best Weekly Performance in 2.5 Years Thanks to New AI

10.07.2026 23:06

Delta's profits were eaten up by record fuel costs. But revenue was buoyed by demand

10.07.2026 21:56

An Unwelcome Measure: Why Kazakhstan Is Abolishing the Mandatory Sale of Foreign Currency Proceeds

10.07.2026 20:51

SK Hynix shares rose 14% to $170 at the start of trading on their debut

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026